{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:56:53Z","timestamp":1759334213322,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: This study aimed to evaluate the immunogenicity and safety of a Meningococcal A and C Polysaccharide Conjugate Vaccine in 3\u20135-month-old infants. A single-center, randomized, blinded, positive-controlled phase III clinical trial was conducted in Binyang County, Guangxi Zhuang Autonomous Region, China. Infants aged 3\u20135 months were randomly assigned to the experimental or control group at a 1:1 ratio. Both groups received 3 primary doses with a 1-month interval between each dose, and a booster dose administered at 18 months of age. Seroconversion rate, seropositivity rate, and GMT of bactericidal antibodies against Neisseria meningitidis groups A and C were assessed, along with adverse reactions within the full course of primary immunization and 30 days after booster immunization. Results: After primary immunization, in the experimental group\u2019s pre-vaccination antibody-negative infants, seroconversion rates for groups A and C exceeded 90%, with antibody fold increases over 90 times; its seroconversion rates and GMT were non-inferior to the control group. Before the 18-month booster, the experimental group\u2019s group A and C antibody seropositivity rates dropped to approximately 70% and 30% (slightly higher than the control), respectively. After booster immunization, the antibody levels against groups A and C were significantly higher than those before the booster and the positive rates and GMT levels of the two groups were similar. Adverse reactions were mainly solicited systemic ones (fever most common), with no statistical difference between groups. Conclusions: The experimental vaccine shows great immunogenicity and safety in infants aged 3\u20135 months and is non-inferior to the control vaccine. In the booster immunization phase of the control group, sequential vaccination with vaccines from different manufacturers was adopted, and the immunogenicity was good.<\/jats:p>","DOI":"10.3390\/vaccines13101023","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:16:29Z","timestamp":1759241789000},"page":"1023","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase III Clinical Trial of Immunogenicity and Safety of Meningococcal A and C Polysaccharide Conjugate Vaccine in Infants Aged 3\u20135 Months"],"prefix":"10.3390","volume":"13","author":[{"given":"Liwei","family":"Shi","sequence":"first","affiliation":[{"name":"Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning 530028, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Services, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., Beijing 100176, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Services, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., Beijing 100176, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoguang","family":"Li","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weicai","family":"Lu","sequence":"additional","affiliation":[{"name":"Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning 530028, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control, Beijing 102629, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjian","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Medical Services, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., Beijing 100176, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3201\/eid1904.111799","article-title":"Description and nomenclature of Neisseria meningitidis capsule locus","volume":"19","author":"Harrison","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jinf.2020.07.025","article-title":"Meningococcal disease surveillance in the Asia-Pacific region (2020): The global meningococcal initiative","volume":"81","author":"Aye","year":"2020","journal-title":"J. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/21645515.2018.1532248","article-title":"Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies","volume":"15","author":"Booy","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: Clinical presentation and sequelae","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/504804","article-title":"Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994\u20132002","volume":"43","author":"Brooks","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2516949","DOI":"10.1080\/21645515.2025.2516949","article-title":"A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi\u00ae (MENACWY-TT)","volume":"21","author":"Dinleyici","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/14760584.2015.1012503","article-title":"Chinese vaccine products go global: Vaccine development and quality control","volume":"14","author":"Xu","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1080\/21645515.2020.1857201","article-title":"Meningococcal vaccines in China","volume":"17","author":"Xu","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1017\/S0950268823000328","article-title":"Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: A literature review","volume":"151","author":"Findlow","year":"2023","journal-title":"Epidemiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1080\/21645515.2018.1445447","article-title":"Meningococcal vaccination in pregnancy","volume":"14","author":"Raya","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/CMR.19.1.142-164.2006","article-title":"Prospects for vaccine prevention of meningococcal infection","volume":"19","author":"Harrison","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.7883\/yoken.JJID.2017.277","article-title":"A Safety and Immunogenicity Study of a Single Dose of a Meningococcal (Groups A, C, W, and Y) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MEN-ACWY-D) in Healthy Japanese Participants","volume":"71","author":"Fukushima","year":"2018","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijid.2016.02.010","article-title":"Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW-D): A multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea","volume":"45","author":"Kim","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jinf.2018.01.007","article-title":"Meningococcal disease and control in China: Findings and updates from the Global Meningococcal Initiative (GMI)","volume":"76","author":"Li","year":"2018","journal-title":"The J. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2071077","DOI":"10.1080\/21645515.2022.2071077","article-title":"Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China, 2010\u20132020: A systematic review and meta-analysis","volume":"18","author":"Xu","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1979846","DOI":"10.1080\/21645515.2021.1979846","article-title":"Preventing invasive meningococcal disease in early infancy","volume":"18","author":"Presa","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_18","first-page":"440","article-title":"Phase III clinical trial on the safety of group A+C meningococcal polysaccharide conjugate vaccine in children aged 3\u201323 months","volume":"028","author":"Wang","year":"2022","journal-title":"Chin. J. Vaccines Immun."},{"key":"ref_19","first-page":"2","article-title":"Observation of adverse reactions after vaccination with lyophilized group A+C meningococcal conjugate vaccine","volume":"11","author":"Fu","year":"2011","journal-title":"China Trop. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/10\/1023\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:28:54Z","timestamp":1759242534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/10\/1023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["vaccines13101023"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13101023","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}